Raising Health
CRISPR by Design with Benjamin Oakes
Feb 20, 2024
Ben Oakes, Scribe Therapeutics cofounder and CEO, discusses his journey in genome editing, transforming bacterial immune systems into genome editing tools. They explore the challenges of engineering these molecules and the potential for life-changing therapeutics. Topics include the intersection of engineering and biology, advancements in gene editing for chronic conditions, and the role of luck in discoveries.
29:20
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Scribe Therapeutics focuses on evolving bacterial immune systems into precise genome editing tools through engineering techniques for more potent, specific, and deliverable systems.
- CRISPR by design approach at Scribe Therapeutics involves defining the ultimate goal and engineering towards it, emphasizing the importance of partnerships for transforming the future of medicine.
Deep dives
Applying Engineering Perspective to Biology at Scribe Therapeutics
Ben Oakes, co-founder and CEO of Scribe Therapeutics, discusses their approach of applying engineering to biology. By starting with the engineering perspective, they can avoid the limitations and challenges of using existing molecules and instead focus on building better versions for genome editing. This approach allows them to make genome editing more potent, safer, and more deliverable, with the goal of transforming genetic medicine to prevent diseases rather than just treat them.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
